| 4.11 -0.28 (-6.38%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.21  |
1-year : | 7.11 |
| Resists | First : | 5.32 |
Second : | 6.09 |
| Pivot price | 5.03 |
|||
| Supports | First : | 4.07 |
Second : | 3.39 |
| MAs | MA(5) : | 4.52 |
MA(20) : | 5.07 |
| MA(100) : | 5.12 |
MA(250) : | 5.77 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 1.4 |
D(3) : | 4.7 |
| RSI | RSI(14): 32.2 |
|||
| 52-week | High : | 9.19 | Low : | 3.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SCYX ] has closed below the lower bollinger band by 5.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ SCYX ] is to continue within current trading range. Bollinger Bands are 1.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.53 - 4.57 | 4.57 - 4.59 |
| Low: | 4.01 - 4.05 | 4.05 - 4.07 |
| Close: | 4.06 - 4.12 | 4.12 - 4.16 |
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Tue, 15 Sep 2026
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development - The Manila Times
Fri, 11 Sep 2026
Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan
Fri, 11 Sep 2026
New Scynexis (SCYX) CFO reports no company shares - Stock Titan
Fri, 11 Sep 2026
SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media
Fri, 11 Sep 2026
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
Wed, 09 Sep 2026
Scynexis Appoints New CFO Amid Transition - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 7.36e+006 (%) |
| Held by Institutions | 2 (%) |
| Shares Short | 348 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -53.3 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 308.5 % |
| Return on Equity (ttm) | -20.9 % |
| Qtrly Rev. Growth | 1.922e+007 % |
| Gross Profit (p.s.) | -74.6 |
| Sales Per Share | -16.56 |
| EBITDA (p.s.) | 1.73153e+007 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.25 |
| Price to Cash Flow | 0.67 |
| Dividend | 0 |
| Forward Dividend | 417670 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|